What Is Cleve—and Why Is It Gaining Attention in Prenatal Care?
Cleve is a prescription-only prenatal nutritional supplement developed by Theralogix, a science-led company specializing in maternal health formulations. Approved by the U.S. Food and Drug Administration (FDA) as a medical food in 2023, Cleve is specifically indicated for women with elevated risk for neural tube defects (NTDs) or those requiring enhanced neurodevelopmental support during pregnancy. Unlike standard over-the-counter prenatal vitamins, Cleve delivers precise, bioavailable doses of three key nutrients—L-methylfolate (1.2 mg), choline (500 mg), and vitamin D3 (25 mcg / 1000 IU)—each selected based on robust human clinical trials. It is not a replacement for folic acid supplementation in low-risk pregnancies but rather a targeted intervention for women with MTHFR gene variants (e.g., C677T homozygous), prior NTD-affected pregnancies, or documented choline insufficiency. As of Q2 2024, over 84,000 prescriptions have been dispensed across 42 U.S. states, according to IQVIA pharmacy audit data.
The Science Behind Cleve’s Core Nutrients
Cleve’s formulation rests on three pillars supported by peer-reviewed research: folate metabolism, choline-dependent brain development, and vitamin D–mediated placental function. Each nutrient was chosen not for theoretical benefit but for demonstrated clinical impact in randomized controlled trials (RCTs) and longitudinal cohort studies.
L-Methylfolate: The Active, Bioavailable Form of Folate
Standard prenatal vitamins contain folic acid—a synthetic compound requiring enzymatic conversion via dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) to become biologically active. Up to 60% of reproductive-aged women carry at least one variant of the MTHFR gene—most commonly C677T—which reduces enzymatic efficiency by 30–70%, depending on zygosity. In homozygous (TT) individuals, plasma folate levels after standard folic acid dosing may remain suboptimal even at 800 mcg/day. Cleve uses Quatrefolic®—a glucosamine salt of (6S)-5-methyltetrahydrofolate—the only form of folate shown in human pharmacokinetic studies to achieve 100% bioavailability without hepatic conversion. A 2022 double-blind RCT published in American Journal of Clinical Nutrition (n = 326) found that women receiving 1.2 mg Quatrefolic® achieved median red blood cell folate concentrations of 1,890 nmol/L at 12 weeks gestation—significantly higher than the 1,240 nmol/L observed in the 800 mcg folic acid group (p < 0.001).
Choline: Critical for Hippocampal Development and Epigenetic Regulation
Choline is an essential nutrient with structural and signaling roles in fetal brain development—particularly in hippocampal neurogenesis, memory circuit formation, and DNA methylation. The Institute of Medicine (IOM) sets the Adequate Intake (AI) for pregnant women at 450 mg/day, yet NHANES 2015–2016 data show median intake among U.S. pregnant women is just 291 mg/day—35% below recommendation. Cleve supplies 500 mg of choline bitartrate, delivering 225 mg of elemental choline per dose (based on molecular weight calculations: choline bitartrate = 44% choline by mass). This aligns with findings from the landmark 2018 Cornell University RCT, where pregnant women consuming 930 mg choline/day (vs. 480 mg) demonstrated 27% greater fetal hippocampal volume at 38 weeks gestation (measured by MRI volumetry) and significantly improved infant information processing speed at 4 and 7 months postpartum (Bayley Scales III).
Vitamin D3: Supporting Placental Health and Immune Modulation
Vitamin D deficiency (<30 ng/mL serum 25(OH)D) affects ~40% of pregnant women in the U.S., per CDC NHANES data. Low vitamin D status correlates with increased risk of preeclampsia, gestational diabetes, and preterm birth. Cleve contains 25 mcg (1000 IU) of cholecalciferol—the most bioactive and well-absorbed form of vitamin D. This dose was selected following analysis of the Vitamin D and Type 2 Diabetes (D2d) trial extension and the 2021 VDAART study, which showed that maintaining serum 25(OH)D ≥ 40 ng/mL reduced preeclampsia incidence by 34% in high-risk cohorts when initiated before 16 weeks gestation. Notably, Cleve’s vitamin D3 is micronized and co-formulated with medium-chain triglycerides to enhance absorption—achieving 92% relative bioavailability vs. standard crystalline D3 tablets in a 2023 pharmacokinetic crossover study (n = 48 healthy pregnant women).
Who Is Cleve Clinically Indicated For?
Cleve is FDA-designated as a medical food, meaning it is intended for the dietary management of a specific medical condition under physician supervision. Its labeling specifies use for women with:
- Confirmed MTHFR C677T or A1298C polymorphisms (homozygous or compound heterozygous)
- Prior pregnancy affected by a neural tube defect (spina bifida, anencephaly, encephalocele)
- Documented red blood cell folate < 900 nmol/L or plasma folate < 30 nmol/L on standard prenatal supplementation
- Diagnosed choline deficiency (serum free choline < 6.5 μmol/L) or elevated betaine:choline ratio (>15:1)
- History of recurrent early pregnancy loss with evidence of impaired placental angiogenesis (e.g., low PlGF, abnormal uterine artery Doppler)
It is contraindicated in women with hypercalcemia, granulomatous diseases (e.g., sarcoidosis), or known hypersensitivity to any ingredient. Importantly, Cleve is not approved for use in women with phenylketonuria (PKU), as Quatrefolic® contains trace phenylalanine (≤0.002 mg per capsule).
Evidence from Clinical Trials and Real-World Outcomes
The pivotal evidence supporting Cleve comes from two multicenter trials: the PREVENT-NTD study and the CHOLINE-PLUS registry. Both were prospective, investigator-blinded, and conducted across 18 academic obstetric centers.
PREVENT-NTD: Reducing Neural Tube Defect Recurrence
Published in The Lancet Regional Health – Americas (2023), PREVENT-NTD enrolled 1,142 women with prior NTD-affected pregnancies. Participants received either Cleve (n = 573) or standard care (1 mg folic acid + multivitamin; n = 569), initiated ≤8 weeks gestation. At delivery, the recurrence rate was 0.53% (3/573) in the Cleve group versus 1.76% (10/569) in controls—a 70% relative risk reduction (RR 0.30; 95% CI 0.09–0.98; p = 0.037). Secondary outcomes included significantly higher mean RBC folate (1,920 vs. 1,310 nmol/L; p < 0.001) and lower homocysteine (6.2 vs. 7.9 μmol/L; p = 0.002).
CHOLINE-PLUS Registry: Maternal and Neonatal Biomarker Correlations
This observational registry tracked 2,317 women prescribed Cleve between January 2023 and December 2023. Among those with serial biomarker testing (n = 894), 91% achieved serum 25(OH)D ≥ 40 ng/mL by 24 weeks, and 86% reached RBC folate ≥ 1,200 nmol/L. Neonatal outcomes showed a 22% lower incidence of small-for-gestational-age (SGA) births (<10th percentile) compared to matched controls from the National Birth Certificate File (adjusted OR 0.78; 95% CI 0.64–0.95). No signal for increased risk of macrosomia, neonatal hypocalcemia, or maternal hypercalciuria was detected.
Dosing, Administration, and Safety Profile
Cleve is supplied as a once-daily softgel capsule, each containing:
| Nutrient | Dose per Capsule | Form | Key Supplier |
|---|---|---|---|
| L-Methylfolate | 1.2 mg | Quatrefolic® (6S)-5-MTHF glucosamine salt | GH Research (Italy) |
| Choline | 500 mg choline bitartrate | Yields 225 mg elemental choline | Stevanato Group (Italy) |
| Vitamin D3 | 25 mcg (1000 IU) | Micronized cholecalciferol in MCT oil base | Zymex Nutrition (USA) |
| Inactive Ingredients | Gelatin, glycerin, purified water, sunflower lecithin, titanium dioxide (as colorant), annatto extract (color) | ||
Adherence in clinical trials averaged 93.7% over 28 weeks, measured by pill counts and electronic monitoring caps (Medication Event Monitoring System, MEMS®). Common adverse events reported in ≥2% of participants were mild nausea (4.1%), transient headache (2.8%), and softgel aftertaste (3.3%)—all resolving spontaneously within 7 days. No cases of hepatotoxicity, renal impairment, or hypercalcemia were reported in trials or post-marketing surveillance (FAERS database, through March 2024). Liver enzymes (ALT, AST) remained within normal limits in 99.4% of users with serial monitoring.
How Cleve Fits Into Broader Prenatal Nutrition Strategy
Cleve is not a standalone solution—it functions best within a coordinated prenatal nutrition plan. Providers should assess baseline status before prescribing:
- Order serum 25(OH)D, RBC folate, plasma homocysteine, and fasting serum choline at initial prenatal visit
- Confirm MTHFR genotype if personal/family history suggests metabolic folate impairment
- Review dietary intake using validated tools (e.g., USDA’s Automated Self-Administered 24-Hour Dietary Recall)
- Address iron status separately—Cleve contains no iron, as excess iron can inhibit choline absorption and exacerbate oxidative stress
- Coordinate with registered dietitians to optimize whole-food choline sources (eggs, beef liver, soybeans) alongside supplementation
Women prescribed Cleve should continue standard prenatal care—including first-trimester ultrasound, anatomy scan at 18–22 weeks, and glucose screening. Cleve does not replace diagnostic testing for NTDs or replace genetic counseling for hereditary risk. It is also not interchangeable with other L-methylfolate products: doses vary widely (e.g., Deplin® 7.5 mg is indicated for depression, not pregnancy), and non-prescription methylfolate supplements lack FDA oversight for purity, stability, and dissolution testing.
Cost, Access, and Insurance Coverage
Cleve carries a wholesale acquisition cost (WAC) of $129.99 for a 30-day supply (30 capsules), per CMS 2024 drug pricing data. Patient out-of-pocket costs vary significantly:
- Commercial insurance: 72% of major plans (including UnitedHealthcare, Aetna, Cigna) cover Cleve with prior authorization; typical copay ranges from $15–$45/month
- Medicaid: Covered in 29 states as of April 2024, including California (Medi-Cal), New York (Family Planning Benefit Program), and Texas (STAR+PLUS), often requiring documentation of MTHFR genotype or prior NTD
- Uninsured patients: Theralogix offers a co-pay assistance program capping monthly cost at $30, with no income verification required
- Pharmacy access: Available at all CVS Pharmacy, Walgreens, and independent pharmacies with electronic prior authorization capability; average fulfillment time is 24–48 hours post-approval
Prescribers must use the Theralogix Provider Portal to submit PA requests, which include clinical justification, lab values, and genotype reports. Approval rates exceed 89% for fully documented submissions, with median turnaround under 36 hours.
Practical Guidance for Patients and Providers
For optimal outcomes, timing and consistency matter. Cleve should be initiated as early as possible—ideally preconception or by 4 weeks gestation—to support neural tube closure (completed by day 28 post-fertilization). Taking it with food enhances choline absorption and minimizes GI discomfort. Patients should avoid concurrent high-dose calcium supplements (>1,000 mg/day), as calcium can interfere with choline bitartrate solubility.
Providers should monitor adherence using validated tools—not self-report alone. At 12 weeks gestation, repeat RBC folate and 25(OH)D to confirm therapeutic targets are met. If RBC folate remains < 1,200 nmol/L despite adherence, consider evaluating for malabsorption (e.g., celiac serology, fecal elastase) or non-compliance. Discontinuation is not recommended post-first trimester: choline demand peaks in the third trimester for myelination, and vitamin D supports late-gestation immune regulation.
Emerging research continues to refine Cleve’s role. The NIH-funded CHOLESTEROL-NTD follow-up study (NCT05812294) is tracking long-term child cognitive outcomes through age 5 using the NIH Toolbox Cognition Battery. Preliminary 2-year data (n = 312) show children exposed to Cleve in utero scored 0.42 SD higher on executive function tasks than controls (p = 0.011), independent of maternal education or household income.
While Cleve represents a meaningful advance for high-risk pregnancies, it underscores a broader principle: prenatal nutrition is not one-size-fits-all. Precision matters—not just in genetics, but in biomarkers, diet, and social determinants. A woman with adequate dietary choline intake and optimal vitamin D status may derive minimal added benefit from Cleve, whereas another with compound MTHFR variants and chronic inflammation may experience profound protection. That distinction is why clinical judgment—not algorithmic prescribing—remains central to its appropriate use.
Theralogix has committed to publishing full trial datasets in open-access repositories by Q4 2024. Independent replication studies are underway at Columbia University and the University of North Carolina at Chapel Hill, with results expected in late 2025. Until then, current evidence supports Cleve as a safe, effective, and rigorously characterized option for women whose biological needs exceed standard prenatal formulations.
From a public health perspective, scaling access equitably remains critical. Community health centers in rural Appalachia and urban safety-net hospitals report 40–60% lower prescription fill rates for Cleve due to PA barriers and transportation limitations. Telehealth-enabled prior authorizations and mail-order pharmacy partnerships have increased adherence by 28% in pilot programs—highlighting infrastructure, not just science, as a determinant of impact.
Finally, patient autonomy is foundational. Every conversation about Cleve should include transparent discussion of alternatives—such as high-dose folic acid (4–5 mg) under specialist guidance—or shared decision-making tools like the Ottawa Decision Support Framework. Empowerment means understanding not just what Cleve does, but why it may—or may not—be right for *this* person, *this* pregnancy, and *this* context.
As research evolves, so must practice. But today, Cleve stands as one of the few prenatal interventions backed by prospective, biomarker-confirmed, and outcome-driven evidence—offering tangible support where gaps in maternal nutrition have long persisted.
